SARS-CoV-2 Infection and Severity in Patients with Hematologic Malignancies: A Systematic Review.

Autor:	SeyedAlinaghi S; Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran., Karimi A; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Mirzapour P; Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran., Salmani R; Department of Midwifery, Khalkhal University of Medical Sciences, Khalkhal, Iran., Razi A; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Mojdeganlou H; Department of Pathology, Urmia University of Medical Sciences, Urmia, Iran., Mojdeganlou P; School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Qodrati M; Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran., Jashaninejad R; Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran., Paranjkhoo P; Turpanjian College of Health Sciences, American University of Armenia, Yerevan 0019, Armenia., Dadras O; Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway., Zarezadeh B; Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran., Afsahi AM; Department of Radiology, School of Medicine, University of California, San Diego (UCSD), California, USA., Afzalian A; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Varshochi S; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Mehraeen E; Department of Health Information Technology, Khalkhal University of Medical Sciences, Khalkhal, Iran., Afsahi G; Department of Biotechnology Research, University of California, San Diego, USA.
Jazyk:	angličtina
Zdroj:	Infectious disorders drug targets [Infect Disord Drug Targets] 2023; Vol. 23 (7), pp. 29-38.
DOI:	10.2174/1871526523666230502142256
Abstrakt:	Introduction: Earlier reports described the possibility of higher SARS-CoV-2 infection and severity in patients with hematological malignancies. Given the importance and incidence of these malignancies, we aimed to systematically review SARS-CoV-2 infection and severity in patients with hematologic cancers. Methods: We retrieved the relevant records by searching the keywords in online databases of PubMed, Web of Science, Cochrane, and Scopus on December 31st, 2021. A two-step screening; title/abstract and full-text screening, was employed to select the eligible studies. These eligible studies entered the final qualitative analysis. The study is adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist to ensure the reliability and validity of the results. Results: Forty studies concerning different hematologic malignancies and the effect of COVID-19 infection on them were included in the final analysis. The findings showed that in general, the prevalence of SARS-CoV-2 infection and the severity of the disease are often higher in hematologic malignancies and the patients could experience higher morbidity and mortality compared to general populations. Conclusion: It appeared that individuals with hematologic malignancies are more vulnerable to COVID-19 infection and they experience more severe disease with higher mortality rates. The presence of other comorbidities could also deteriorate this situation. Further investigation is recommended to evaluate the outcome of COVID-19 infection in different subtypes of hematologic malignancies. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu